Screener
Alkermes ALKS Vivitrol — Actual Credits Received Related To Duplicate Billings
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alkermes in its filing.
Tagged under the XBRL concept alks:ActualCreditsReceivedRelatedToDuplicateBillings.
The source filing: Alkermes’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 9:22 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-319022
The decrease in Medicaid rebates as a percentage of sales was primarily due to gross-to-net favorability, as actual Medicaid rebates related to VIVITROL and ARISTADA/ARISTADA INITIO were lower than original estimates during the six months ended June 30, 2026 by approximately $8.9 million and $8.1 million, respectively.
Item 1. Condensed Consolidated Financial Statements:
FAQ
- What is Alkermes's vivitrol — actual credits received related to duplicate billings?
- Alkermes (ALKS) reported vivitrol — actual credits received related to duplicate billings of $8.9M in Q2 2026.
- How has Alkermes's vivitrol — actual credits received related to duplicate billings changed year-over-year?
- Alkermes's vivitrol — actual credits received related to duplicate billings decreased by 49.7% year-over-year, from $17.7M to $8.9M.
- What does vivitrol — actual credits received related to duplicate billings mean?
- This metric tracks the financial adjustments or refunds received from customers or distributors due to invoicing errors where the same product shipment was billed multiple times. It serves as an indicator of the operational efficiency and accuracy of the company's accounts receivable and order-to-cash processes. High or recurring values may suggest systemic weaknesses in billing controls or supply chain management.
Ask your AI about Alkermes's vivitrol — actual credits received related to duplicate billings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude